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The pharmacodynamic profile of
“Blackadder” blackcurrant juice effects
upon the monoamine axis in humans:
A randomised controlled trial
Anthony W Watson 1,2, Arjan Scheepens2, David O Kennedy1, Janine
M Cooney 2AQ2
¶
, Tania M Trower2, Crystal F Haskell-Ramsay1
1Brain, Performance and Nutrition Research Centre, Northumbria UniversityAQ3
¶
, 2The New Zealand Institute for
Plant & Food Research Limited
Emerging evidence from human intervention trials indicates health benefits of consuming blackcurrant fruit,
including improvements to cognitive performance, modulation of blood flow, regulation of blood glucose and
inhibition of enzymes underpinning normal cognitive function. Of particular relevance is our previous
demonstration of monoamine oxidase (MAO)-A and B inhibition after the consumption of a New Zealand
“Blackadder” blackcurrant juice in humans.
The current study uses a double-blind, placebo-controlled, randomised cross- over design to assess the
pharmacodynamics of the effects on platelet MAO-B inhibition and associated substrates, plasma prolactin
levels and blood glucose levels after consumption of a single serve of “Blackadder” blackcurrant juice
standardised to 500 mg polyphenols. Eight healthy male (20-–35 years) participants completed the trial.
Measurements were obtained at baseline 15, 30, 45, 60, 100, 120, 150, 180, 240 mins and 24 h post dose.
A fast, absolute and reversible inhibition of blood platelet MAO-B (P< 0.001) and a significant but delayed
reduction in plasma prolactin (P< 0.001) were observed following the consumption of “Blackadder”
blackcurrant juice when compared to a placebo control. No interpretable changes in substrates of MAO or
associated metabolites were seen.
These data provide a clear time course of the reversible inhibition of MAO-B after the single consumption of
a of New Zealand “Blackadder” blackcurrant juice standardised at 500 mg of polyphenols and, therefore,
provide a therapeutic window on which to base future nutritional interventions.
Keywords: Monoamine oxidase, Blackcurrants, Prolactin, Pharmacodynamics
Introduction
Blackcurrants (Ribes nigrum) are a berry fruit high in
polyphenols when compared to other similar berries1,
with 3-O-glucosides and the 3-O-rutinosides of antho-
cyanins delphinidin and cyanidin representing the
major phenolic constituents2. Other phenolic struc-
tures, such as phenolic acids are also present in
smaller quantities3. Emerging evidence supports
health benefits of consuming blackcurrant fruit,
including modulation of blood flow4,5 and brain
wave spectral activity6; improvements to cognitive per-
formance7, and inhibition of monoamine oxidase
(MAO) enzymes in humans7.
Monoamine oxidase enzyme isoforms -A and -B are
present in the periphery and the central nervous system
and play a major role in the metabolism of both
dietary and endogenous monoamines8. MAO-A pre-
ferentially catalyses the oxidation of serotonin;
MAO-B is more active towards β-phenylethylamine
and benzylamine; whereas dopamine, adrenaline, nor-
adrenaline tryptamine and tyramine are oxidised by
both isoforms9. Inhibition of MAO therefore results
in an increased concentration of monoamine neuro-
transmitters and, in the case of MAO-B inhibition, is
well documented as a therapeutic treatment for
Parkinsonian symptoms10. Monoamine inhibition
can be reversible or irreversible and can either act
non-selectively, affecting both isoforms, or selectively,
affecting only one isoform. For example, phenelzine is
an irreversible, non-selective MAO inhibitor, which
inhibits both MAO-A and B for up to three weeks11;
in contrast, toloxatone, a reversible inhibitor of
MAO-A (RIMA), inhibits MAO-A for only six
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hours before activity returns to baseline values12. This
selective inhibition is preferable as the inhibition of
both MAO isoforms can in some instances prevent
the degradation of dietary amines in the digestive
tract and if this continues for prolonged periods tyra-
mine can accumulate to dangerous levels, potentiating
a hypertensive crisis. It is therefore important to ident-
ify reversible and/or selective MAO inhibitors.
Our previous demonstration of MAO inhibition fol-
lowing blackcurrant consumption, outlined the effi-
cacy of a cold-pressed blackcurrant juice
(“Blackadder” cultivar) in inhibiting both MAO iso-
forms in the periphery. These findings were coupled
with a non-significant reduction in plasma prolactin,
potentially indicating modulations in circulating dopa-
mine levels7. This inhibition, observed in healthy
young adults measured at ∼2 h post consumption,
was particularly striking for MAO-B indicating an
almost complete inhibition (96%). It is therefore of
great importance to ascertain the pharmacodynamics
of this action in order to establish if it is safe, reversible
and to determine the optimal timing of dosing. A mild
increase in blood glucose was also observed when
measured at 1 and 2.5 h post consumption of
“Blackadder” blackcurrant when compared to
control. This increase is contrary to expectation
based upon a previous observation of decreased
post-prandial peak blood glucose levels following
apple juice13. It is theorised that attenuation of
glucose absorption is due to inhibition of sodium-
glucose transport proteins in the gut lumen after
exposure to phenolic acids14. Therefore, the previously
observed higher blood glucose readings may have been
due to a slowing of glucose uptake following consump-
tion of “Blackadder” blackcurrant, rather than an
overall increase in blood glucose. It is therefore impor-
tant that the current study investigates more frequent
time points to establish a pattern of glucose modu-
lation after consumption of “Blackadder” juice.
The current study will assess the pharmacodynamics
of peripheral MAO-B inhibition, associated catechol-
amine and prolactin levels, and venous blood glucose
profile following consumption of “Blackadder” black-
currant. The trial will utilise the 500 mg/60 kg of body
weight dose of cold pressed “Blackadder” juice (equiv-
alent to∼100 g of fresh fruit) which was shown to have
MAO inhibitory effects in our previous report and
effects will be measured in a cohort of healthy male
adult volunteers.
Materials and methods
Design
The study followed a double-blind, counterbalanced,
placebo-controlled, repeated measures design.
Participants were randomly allocated to treatment
orders as selected through a Williams Latin Square15.
Participants
Eight healthy male adults participated in the study and
provided all samples at all time points. Participant
characteristics can be found in Table 1. Women were
omitted due to changes in circulating prolactin levels
during the menstrual cycle16. Power analysis was deter-
mined using post dose monoamine-B activity levels
after supplementation with a similar blackcurrant
juice as described in our previous paper7. A two
tailed A priori power analysis using G-power17 was
used to indicate the samples size needed to achieve
an alpha error probability of 0.01. The power analysis
indicated that a sample size of 7 would be needed to
achieve a power of 0.99.
Participants were recruited using opportunity
sampling. Participants received £70 to recompense
them for any expense they may have incurred to par-
ticipate in the trial. Before participants were enrolled
in the study they attended a 20 min screening session.
During this screening session participants gave their
informed consent to participate in the study and
were screened for any contraindications to the study
with the use of an exclusion questionnaire. Exclusion
criteria included: Risk or diagnosis of blood-borne
disease, diagnosed history of any psychiatric disorder,
aged under 18 or over 35 years, BMI above 30 kg/m2
or below 17 kg/m2, diagnosis of diabetes or current
use of prescription, over-the-counter or recreational
drugs. Recruitment ceased when eight full sets of
data were successfully attained.
The study received ethical approval (RE20-10-
11208) and was conducted according to the
Declaration of Helsinki (1964).
Treatments
The “Blackadder” juice was assessed for phytochem-
ical profile using the method described by Schrage
et al.,18. Participants received two drinks with at
least one week washout between treatments. These
drinks contained either 0 mg of polyphenols
(control) or ∼500 mg/ polyphenols per 60 kg of
body weight in the form of a cold-pressed New
Zealand blackcurrant juice (“Blackadder” cultivar).
Dose ranges of individual phenolic constituents can
be found in Table 2 and total dose ranges of phenolic
groups can be found in Table 3.
Drinks were matched for sugars and taste. In each
case, drinks comprised of 3.44 g of glucose, 4.63 g of
Table 1 Mean participant characteristics
Measure Average measurement SD Range
Age (years) 25.3 4.7 20–35
Height (m) 1.81 0.07 1.7–1.95
Mass (kg) 82.31 4.73 75–89
BMI (kg/m2) 24.99 2.01 21–27
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fructose, 0.8 g of sucrose, 6 g of SplendaTM and 50 ml
of blackcurrant flavouring (Schweppes blackcurrant
cordial). The total volume of the drink was made up
to 200 ml with water and served chilled in an opaque
brown bottle by an independent third party. All quan-
tities discussed are based on a 60 kg person, drink
quantities were calculated per kilo of body weight. A
breakdown of anthocyanins and other phenolics in
the study drinks can be seen in Tables 2 and 3.
Blood collection and storage
Blood was collected from an inlaying cannula in the
left median cubital vein (21 Gauge, Becton,
Dickinson and Company, UK). Venous blood
samples (15 ml) were collected at baseline and 10
further time points post consumption of study treat-
ments. Samples were collected in either BD
Vacutainers© (Becton, Dickinson and company) or
with 20 µl end-to-end capillary (EKF Diagnostics).
Vacutainer receptacles were treated with anticoagu-
lants, one with lithium heparin (LH) and one with
ethylenediaminetetraacetic acid (EDTA). Whole
blood samples treated with LH were immediately cen-
trifuged (4°C, 5000 rpm, 10 min) (Hitachi Himac pre-
parative ultracentrifuge model CP100MX). Plasma
was then extracted and aliquoted into 1.5 ml
Eppendorf© tubes and stored at −80°C until analysis.
Whole blood samples treated with EDTAwere used to
isolate platelet cells prepared for storage using the
methods as described by Snell et al.,19. Prepared plate-
let pellets were stored at −80°C until MAO-B activity
analysis was performed.
Table 2 Phytochemical constituents of “Blackadder”
blackcurrant juice (mg/100 ml of raw juice and dosing range
supplemented)
Compound
Quantity (mg/
100 ml) Dose range mg
3-Caffeoylquinic acid 6 5.88–6.97
Caffeoylhexose 2.5 2.50–2.97
3-p-Coumaroylquinic
acid
5.7 5.63–6.68
Epigallocatechin 4.9 4.88–5.79
Delphinidin 3-O-
glucoside
47.7 47.13–55.92
Delphinidin 3-O-
rutinoside
184.6 182.38–216.42
Cyanidin 3-O-glucoside 20.6 20.38–24.18
Cyanidin 3-O-rutinoside 206.5 204.00–242.08
Petunidin 3-O-rutinoside 3.5 3.50–4.15
Pelargonidin 3-O-
rutinoside
3.7 3.63–4.30
Peonidin 3-O-rutinoside 5.4 5.38–6.38
Myricetin 3-O-rutinoside 15.3 15.13–17.95
Myricetin 3-O-glucoside 2.2 2.13–2.52
Quercetin 3-O-rutinoside 3.6 3.50–4.15
Quercetin 3-O-glucoside 2 2.00–2.37
Quercetin 3-O-pentoside 1.7 1.63–1.93
Myricetin 2.2 2.13–2.52
Total anthocyanins 474 465–555
Total polyphenols 636 624–744
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MAO analysis
Isolated platelet pellets were prepared using methods
described by Watson et al.,7 and analysed for MAO-
B activity using the Amplex® Red Monoamine
Oxidase-B Assay Kit (A12214 Invitrogen), as per
manufacturer’s instructions.
Circulating 3,4-dihydroxyphenylglycol (DHPG)
was used as a proxy for MAO-A activity20. This
method has been used in many pharmacological
MAO inhibitor studies20,21.
Prolactin analysis
Prolactin analysis was conducted by Diagnostic
Medlab, Auckland, New Zealand in 300 µl of LH
treated blood plasma.
Catecholamine Analysis
Catecholamines and associated metabolites were ana-
lysed in plasma to assess the impact of MAO activity
on associated substrates.
Materials
Formic acid (Riedel-de Haën), ammonium formate
and acetic anhydride (Fluka), were purchased from
Sigma Aldrich (Auckland, New Zealand). Di-sodium
tetraborate (BDH) was purchased from Global
Science (Auckland, New Zealand). Optima LC/MS
grade acetonitrile (Fisher Scientific) was purchased
from ThermoFisher (Auckland, New Zealand).
Water was of Milli-Q grade. Analytical standards,
dopamine, normetadrenaline, noradrenaline, adrena-
line, 3,4-dihydroxyphenylglycol (DHPG), serotonin,
3,4-dihydroxyphenylacetic acid (DOPAC), L-3,4-dihy-
droxyphenyl alanine (DOPA) and homovanillic acid
(HMV) were purchased from Sigma-Aldrich and phe-
nylethylamine (PEA) from Acros Organics (Geel,
Belgium). Deuterated acetic anhydride [d6] was pur-
chased from Sigma-Aldrich and deuterated dopamine
[d4] and DOPA [d3] from CDN Isotopes (Quebec,
Canada).
Standard Preparation
Individual stock standards (1000 mg/ml) (PEA, dopa-
mine, serotonin, normetadrenaline, noradrenaline,
adrenaline, DHPG, DOPAC, DOPA and HMV)
were prepared in 0.1% formic acidaq, and used to
create a mixed catecholamine standard of all com-
pounds (10 mg/ml). Two separate labelled internal
standards for spiking and recovery were also prepared
(IS1) DOPA [d3] 10 mg/ml and (IS2) dopamine [d4]
10 mg/ml. One hundred millilitres of each of these
standards was derivatised separately, as described for
the samples, to prepare a derivatised mixed standard,
and two derivatised internal standards (IS1 and IS2).
The derivatised mixed standard was used to prepare
calibration standards in the range 0.02 ng/ml to
5 ng/ml.
To facilitate quantitation and to correct for matrix
effects during analysis, labelled internal standards for
each analyte were prepared (d-IS) by derivatising
100 ml of the mixed catecholamine standard (10 mg/
ml), as described for the samples, with the exception
that deuterated acetic anhydride [d6] was used in
place of unlabelled acetic anhydride.
All calibration standards were spiked with 10 ml of
the derivatised internal standards [(IS1) DOPA [d3]
100 ng/ml and (IS2) dopamine [d4] 100 ng/ml; final
concentration 1 ng/ml] and 100 µl of the derivatised
labelled internal standard catecholamine mixture
[(d-IS) 10 ng/ml; final concentration 1 ng/ml] and
prepared at a final volume of 1 ml.
Sample Preparation
Plasma samples were treated to remove proteins and
derivatised in two stages to acetylate alcohol and
amine functional groups prior to LC-MS analysis.
A double derivatisation was found to be necessary
to acetylate the less reactive alkyl hydroxyl groups.
Briefly, each plasma sample (200 µl) was added to
a 1.5 ml microtube already containing 600 µl cold
acetonitrile, 100 µl acetic anhydride and 10 µl
100 ng/ml DOPA d3 [(IS1); final concentration
1 ng/ml] and mixed well. Samples were chilled at
−80oC for 15 min then centrifuged at 16100 g for
15 min, and the filtrate transferred to a 15 ml screw
capped glass culture tube. A further 200 µl aceto-
nitrile was added to each microtube, mixed, centri-
fuged at 16100 g for 15 min and the filtrate
combined with the original filtrate. To each com-
bined sample filtrate 10 µl 100 ng/mL dopamine d4
[(IS2); final concentration 1 ng/ml] was added and
the samples derivatised by the addition of 200 µl
100 mM borate buffer (3.81g in 100 ml of water)
and 100 µl acetic anhydride and microwaved at
30% power for 15 min. Samples were then evapor-
ated to just dry with nitrogen at 50oC. Samples
were re-derivatised; 100 µl acetonitrile, and 100 µl
acetic anhydride and microwaved at 30% power for
15 min. Finally, to each sample 100 µl of the deriva-
tised labelled internal standard catecholamine
mixture [(d-IS) 10 ng/ml; final concentration 1 ng/
mL] was added, and the samples made up to 1 ml
with water and transferred to an autosampler vial
ready for analysis.
LC-MS Analysis
Analysis of catecholamines was performed using an
AB Sciex Qtrap 5500 equipped with a Turbo V electro-
spray source (ESI) (AB Sciex, Foster City, California,
USA), coupled to a Dionex UltiMate 3000 HPLC
system, which consisted of two UltiMate 3000 RS
pumps, an UltiMate 3000 RS autosampler and an
UltiMate 3000 RS column compartment (Dionex,
Watson et al. The pharmacodynamic profile of “Blackadder” blackcurrant juice effects upon the monoamine axis in humans
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Olten, Switzerland) and controlled with Analyst 1.5.2
software. A 150 by 2.1 mm Atlantis® T3 analytical
column, (3 µm particle size; Waters Corp., Milford,
MA, USA) maintained at 50oC was used. Solvents
were (A) MilliQ water+ 0.03% ammonium formate
+ 0.1% formic acid and (B) acetonitrile+ 0.1%
formic acid and the flow rate was 0.6 ml/min. The
initial mobile phase, 100% A, was ramped linearly to
70% A at 12 min, 30% A at 15 min, and 0% A at
15.5 min and held for 4 min before resetting to the
original conditions. Sample injection volume was
50 µl.
The ESI conditions were: gas 1, nitrogen (40 psi);
gas 2, nitrogen (50 psi); ion spray voltage, 2500 V;
ion source temperature, 700oC; curtain gas, nitrogen
(50 psi). LC/MS data was acquired in the positive
mode using the most intense selected reaction moni-
toring (SRM) transition for each compound. In
some cases the ammonium adduct was the most abun-
dant ion observed for Q1. A detailed description of
analyte specific MS parameters is given in Table 4.
Quantitation was performed using the internal stan-
dard ratio method using MultiQuant software.
Glucose and lactate analysis
Twenty microlitres of whole blood were collected from
the inlaying cannula in an end-to-end capillary (EKF
Diagnostics, Surrey, UK) and immediately transferred
into an EKF safe-lock cup prefilled with 1 ml of hae-
molysis solution. The whole blood in haemolysis sol-
ution was then analysed using a Biosen C_line
analyser (EKF Diagnostics, Surrey, UK) for glucose
(mmol/L) and lactate (mmol/L) within 30 min of col-
lection. The manufacturer reports that the Biosen
C_line analyser has a coefficient of variance of 1.5%.
Procedures
Participants were required to attend the laboratory a
total of three times. The first was a screening visit to
ensure eligibility, the second and third were study
visits. On all study day visits, participants arrived in
the laboratory at 8 am and confirmed that they had
fasted for 12 h prior and were in good health. An inlay-
ing cannula was then inserted into the participants left
median cubital vein by a qualified phlebotomist.
Fifteen millilitres of blood were then drawn from the
cannula using a 5 ml vacutainer containing EDTA
and a 10 ml vacutainer containing LH. Depending
upon randomised treatment allocation, the participant
then consumed either “Blackadder” juice or the
matched control. Drinks were presented to partici-
pants chilled in a sealed opaque bottle and they were
given 5 min to consume the drink through a straw. A
further 15 ml of blood was then removed via the
cannula; at; 15, 30, 4560, 100, 120, 150, 180 and
240 min post consumption. Participants were then
free to leave. Participants were required to attend a
24 h follow up visit where 15 ml of blood was obtained
via venepuncture. Diet was controlled (nil by mouth
other than water) during the 4 h period after consump-
tion of the treatments. There was no standardisation of
food intake across visits during 4–24 h. Participants
were however asked to consume no purple coloured
berries. A graphical representation of the study
design can be seen in Fig. 1.
Statistical analysis
Data from baseline through to 240 min post-consump-
tion were analysed to assess the Cmax and Tmax of the
biological parameters up to four hours post dose.
Twenty-four hour follow-up data was analysed to
assess if values had returned to baseline 24 h post-
dose.
For all blood parameters an estimation of the area
under the curve (AUC) was calculated using the incre-
mental trapezoidal method. AUC was calculated
incrementally from time point; 0 to 15, 15 to 30, 30
to 45, 45 to 60, 60 to 100, 100 to 120, 120 to 150,
150 to 180 and 180 to 240 min using “unchanged”
raw data (iAUC). Increments were then summed to
give an area under the curve from time point zero, to
the last observed study day concentration at 240 min
post consumption (AUCo−t).
Table 4 MRM Transitions used for catecholamines and their
isotopically labelled internal standard analogues
Q1 Q3 Time Name DP EP CE CXP
344 197 8.65 DOPA d3 (IS1) 70 10 35 16
353 201 8.58 DOPA d3 [d9] 70 10 35 16
341 194 8.67 DOPA 70 10 35 16
350 198 8.60 DOPA [d9] 70 10 35 16
164 105 8.98 PEA 30 10 25 10
167 105 8.95 PEA [d3] 30 10 25 10
261 160 9.75 Serotonin 10 5 25 1
267 161 9.70 Serotonin [d6] 10 5 25 1
284 141 9.81 Dopamine [d4]
(IS2)
70 10 37 15
293 143 9.74 Dopamine [d4]
[d9]
70 10 37 15
280 137 9.85 Dopamine 70 6 35 15
289 139 9.78 Dopamine [d9] 70 6 35 15
242 137 9.89 HMV 50 10 30 16
245 137 9.85 HMV [d3] 50 10 30 16
270 165 9.93 DOPAC 50 10 15 15
276 168 9.87 DOPAC [d6] 50 10 15 15
250 166 10.58 Normetadrenaline 50 9 25 15
256 168 10.50 Normetadrenaline
[d9]
50 9 25 15
355 194 10.61 Noradrenalin 10 10 30 1
367 199 10.51 Noradenalin [d12] 10 10 30 1
292 250 12.19 Adrenalin 170 10 20 1
301 257 12.09 Adrenalin [d12] 170 10 20 1
356. 237 14.09 DHPG 90 13 20 20
368 244 14.05 DHPG [d12] 90 13 20 20
Declustering potential (DP), entrance potential (EP), collision
energy (CE), collision cell exit potential (CXP) retention time
(time), parent ion (Q1) and product ion (Q3).
Watson et al. The pharmacodynamic profile of “Blackadder” blackcurrant juice effects upon the monoamine axis in humans
5
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
Treatment effects were analysed with linear mixed
models (LMM) including the terms treatment, assess-
ment, treatment x assessment as fixed effects for AUC.
Pairwise comparisons corrected for least squares
difference, were conducted on all outcomes with a P
value <0.05 from the initial mixed model analysis to
ascertain any differences between treatments for the
whole session and at specific epochs. Twenty-four
hour assessments were analysed on “raw” values
using repeated measures LMM including the terms
treatment x assessment (baseline and 24h) as fixed
effects. All data were tabulated using Microsoft
Excel 2013 and analyses were conducted with IBM
SPSS Statistics 22.
Results
Analysis of baseline data revealed there were no sig-
nificant pre-dose differences between treatments on
any measures. Area under the curve data can be
found in Table 5. Twenty-four hour post-data are pre-
sented in Table 6. Outcomes that elicited a significant
effect in the initial LMM are outlined below.
Platelet MAO-B activity
Analysis of AUCo-t data revealed a significant effect of
treatment [F(1,12.43)= 67.2, P< 0.001]. This was
observed to be due to a significant reduction in AUC
platelet MAO-B activity after consumption of
“Blackadder” when compared to control. Analysis of
iAUC data revealed a significant treatment*increment
interaction [F(8,14.77)= 13.00, P< 0.001]. Pairwise
analysis of the increments revealed significantly
lower iAUC at, 15–30 (P< 0.001), 30–45 (P=
0.002), 45–60 (P< 0.001), 60–100 (P= 0.001), 100–
120 (P< 0.001), 120–150 (P< 0.001), 150–180 (P<
0.001) and 180–240 min (P= 0.001) following
“Blackadder” when compared to control. There were
no significant effects of treatment at the 24 h time
point. Please see Fig. 2A.
Prolactin
Analysis of AUCo−t data revealed a significant effect
of treatment [F(1,13)= 6.24, P= 0.027]. This was
observed to be due to a significant reduction in prolac-
tin after consumption of “Blackadder” when com-
pared to control. Analysis of iAUC data revealed a
significant treatment*increment interaction [F
(8,24)= 3.12, p0.012]. Pairwise analysis of the incre-
ments revealed significantly or trend to significantly
lower iAUC at 45–60 (P= 0.083), 60–100 (P=
0.009), 100–120 (P< 0.03), 120–150 (P= 0.012),
150–180 and (P= 0.05) following “Blackadder”
when compared to control. There were no significant
effects of treatment at the 24 h time point. Please see
Fig. 2B.
Discussion
Results from this randomised, placebo-controlled,
double blind, counterbalanced cross-over trial demon-
strate a fast and absolute inhibition of blood platelet
MAO-B and a significant reduction in plasma prolac-
tin induced by the consumption of the New Zealand
“Blackadder” blackcurrant juice when compared to
a placebo control.
The current study illustrates a sustained significant
reduction in peripheral platelet MAO-B activity of
∼100% by consuming “Blackadder” blackcurrant
when compared to control. This reduction began
within 15 min of consumption, during the first post-
dose epoch measured, and continued to be signifi-
cantly reduced through to four hours post dose, that
being the last measurement on the day of treatment.
Platelet MAO-B activity had returned close to the
pre-dose baseline level 24 h post dose. Due to the
extremely rapid inhibition of the platelet MAO-B
enzyme, it is not possible to calculate a time to
maximal inhibition. It would therefore be useful if
future studies were conducted using several doses
and shorter initial blood collection epochs. The
profile of MAO-B inhibition of “Blackadder” juice
bears a notable similarity, to pharmaceutical reversible
MAO-B specific inhibitors such as lazabemide, which
have shown a rapid inhibition of MAO-B in platelets
of >90% at 30 min post dose, with maximal inhibition
subsiding 16 h post dose and full restoration of enzyme
Figure 1 Study day running order. Scale depicts minutes post supplementation of the study intervention. CRF= case report
form.
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Table 5 Incremental and total AUC data for the control and “Blackadder” blackcurrant (Ribes nigrum) for blood outcomes MAO-B prolactin, glucose and lactate and linear mixed model outcomes
Outcome Treatment N
0 to 15 min 15 to 30 min 30 to 45 min 45 to 60 min 60 to 100 min 100 to 120 min 120 to 150 min 150 to 180 min 180 to 240 min Total AUC
Effect of
treatment
Treatment*
increment interactionMean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
MAO-B (ng/ml) Control 7 17305 5835 16850 6095 14774 4600 15052 4066 34649 9936 40411 17103 43400 18830 44437 17936 91500 35631 318379 112471 F= 67
P< 0.001
F= 13 P< 0.001*
“Blackadder” 12758 8394 1375 2390 63 166 0 0 0 0 0 0 1195 2317 2339 2774 8834 9370 26564 19634
Prolactin (ng/ml) Control 8 4232 980 3665 793 3391 795 3208 861 6349 1872 6318 1997 5820 2172 5465 2209 11023 4879 49472 14764 F= 6.24
P< 0.001
F= 3.12 P= 0.012
“Blackadder” 4155 927 3523 834 3074 799 2739 744 4514 1127 3733 1014 3557 1174 3753 1399 8286 3928 37333 11362
Glucose mmol/ml) Control 8 76.20 14.79 87.06 21.78 73.67 20.82 57.57 15.90 108.13 20.54 113.64 12.48 118.58 9.23 122.21 8.01 249.45 8.52 894.68 450.71 F= 0.12= 0.91 F= 2.08 P= 0.01*
“Blackadder” 69.39 9.39 77.64 15.16 75.34 16.37 64.04 18.52 112.33 21.81 113.44 12.88 118.95 9.64 123.60 11.03 248.44 15.99 891.71 451.11
Lactate (ng/ml) Control 8 13.65 5.16 19.48 8.54 21.83 7.30 20.06 6.17 30.88 10.13 21.88 7.42 20.14 5.92 21.58 5.86 43.84 12.31 213.33 56.17 F= 1.55> 0.25 F= 1.58= 0.15
“Blackadder” 14.31 5.30 16.76 5.88 20.80 7.09 22.35 6.15 36.58 7.00 27.84 6.20 23.46 6.76 22.14 6.32 42.21 15.87 226.45 49.07
Noradrenaline (ng/
ml)
Control 8 10.13 2.31 10.55 3.61 10.22 4.75 11.68 6.77 24.56 11.75 23.04 9.03 22.29 8.69 20.88 7.37 39.13 11.43 172.49 54.90 F= 0.97
P= 0.33
F= 0.74.47 P= 0.65
“Blackadder” 7.03 1.54 7.56 2.16 8.15 3.12 9.53 3.68 19.28 7.45 17.99 8.64 19.31 9.28 21.38 6.60 42.02 12.00 152.25 49.77
Normetadrenaline
(ng/ml)
Control 8 6.97 2.60 7.72 4.22 7.39 5.25 8.95 7.48 17.48 14.29 14.04 10.93 14.22 8.98 11.99 4.22 21.64 5.69 110.39 52.62 F= 0.01
P= 0.92
F= 1.03.47 P= 0.42
“Blackadder” 4.99 3.32 6.02 3.85 6.25 3.69 6.99 3.47 14.80 7.96 13.13 7.35 13.32 6.30 14.47 5.41 27.94 8.06 107.92 38.80
Serotonin (ng/ml) Control 8 394.78 248.33 319.90 226.52 258.87 161.54 232.74 140.4 978.90 572.89 1481.13 944.93 1254.10 746.35 1071.53 728.45 1322.57 861.70 7314.52 3846.21 F= 0.17
P= 0.68
F= 0.40 P= 0.90
“Blackadder” 438.13 361.61 333.94 239.81 248.67 141.85 215.24 82.75 752.41 417.04 1110.16 884.23 1056.18 722.17 919.20 598.86 1455.84 818.52 6529.76 3678.81
Dopamine (ng/ml) Control 8 5.93 6.17 5.51 5.43 4.41 5.03 4.20 4.77 7.74 6.94 6.91 6.40 6.51 5.32 5.30 3.60 9.11 7.05 55.62 45.00 F= 1.56
P= 0.22
F= 0.69 P= 0.69
“Blackadder” 2.60 1.58 2.64 1.38 2.16 0.94 2.53 1.31 5.23 3.03 4.18 2.33 4.47 1.99 5.25 3.23 10.48 6.25 39.54 15.87
DHPG (ng/ml) Control 8 18.46 5.01 18.68 6.55 17.99 6.42 20.96 6.54 38.04 13.79 34.11 8.32 37.75 9.90 40.85 12.96 84.81 28.62 310.29 56.80 F= 1.93
P= 0.17
F= 0.33 P= 0.94
“Blackadder” 16.55 4.72 15.91 5.61 14.28 5.93 14.71 7.55 28.61 21.90 27.35 26.17 31.12 20.70 34.98 13.63 73.61 20.14 255.27 111.54
DOPAC (ng/ml) Control 8 54.47 21.98 54.23 20.11 46.70 16.57 47.26 15.63 99.98 38.35 94.17 36.94 95.50 31.06 92.04 21.23 176.83 41.90 761.18 213.20 F= 0.59
P= 0.44
F= 0.97 P= 0.47
“Blackadder” 57.97 23.21 52.02 22.85 48.05 21.14 47.68 16.36 84.71 25.72 73.58 30.39 78.54 37.11 88.00 40.72 178.93 68.06 709.47 269.69
DOPA (ng/ml) Control 8 22.49 8.99 23.00 8.83 21.87 8.29 20.56 9.21 43.89 16.51 45.89 12.80 51.71 17.84 52.54 22.08 110.57 44.57 391.29 101.25 F= 1.43
P= 0.24
F= 0.71 P0.67
“Blackadder” 23.94 9.52 20.72 6.69 20.14 7.84 22.18 9.49 44.02 11.13 38.45 8.68 42.45 9.52 45.59 17.13 82.63 36.46 337.12 91.05
PEA (ng/ml) Control 8 0.75 0.44 0.73 0.32 0.65 0.35 0.64 0.33 1.36 0.55 1.44 0.76 1.36 0.80 1.18 0.62 2.87 1.24 10.99 4.99 F= 0.55
P= 0.46
F= 1.66 P= 0.14
“Blackadder” 0.68 0.29 0.75 0.34 0.71 0.35 0.86 0.40 1.91 1.00 1.43 0.76 1.38 0.49 1.56 0.53 2.76 0.76 11.89 4.03
HMV (ng/ml) Control 8 183.25 52.42 182.55 43.60 184.58 48.48 176.00 51.91 333.74 72.15 296.84 55.03 287.49 47.86 279.83 46.30 544.37 78.47 2461.11 436.17 F= 0.21
P= 0.64
F= 0.65 P= 0.72
“Blackadder” 212.44 87.91 202.63 87.52 183.79 76.57 179.82 50.86 326.59 81.82 281.32 77.11 256.87 95.35 256.36 56.27 483.77 87.04 2367.79 676.80
Monoamine oxidase-B (MAO-B); Homovanillic acid (HVA); 3,4-Dihydroxyphenylacetic (DOPAC); Dihydroxyphenylalanine (DOPA); phenylethylamine (PEA); 3,5-Dihydroxyphenylglycine (DHPG.
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activity returning 48 h post dose following a 100 mg
dose of lazabemide22. The active compound or com-
pounds driving the inhibition in the present study are
currently not known. Data in the literature outline
an inhibition of MAO-B by anthocyanins in vitro23;
however, this study used levels 1000 times higher
than quantified in plasma after oral consumption7.
In addition maximal plasma concentrations of
Table 6 Mean change from baseline scores, standard deviations and LMM outcomes for all 24 h parameters
Measure Treatment N
Baseline 24h
Treatment* repetition effectMean SD Mean SD
MAO-B Control 7 1074.40 376.60 1739.99 681.07 F= 1.99 P= 0.171
(nmol H2O2) “Blackadder” 1526.02 1095.21 1417.86 542.26
Prolactin Control 8 308.32 86.65 332.67 120.66 F= 0.72 P= 0.79
(mIU/L) “Blackadder” 296.46 69.68 301.01 122.47
Glucose Control 8 4.26 0.47 4.50 0.35 F= 0.17 P= 0.68
(mmol/L) “Blackadder” 4.23 0.44 4.34 0.60
Lactate Control 8 0.72 0.23 1.01 0.44 F= 0.335 P= 0.56
(mmol/L) “Blackadder” 0.93 0.37 0.66 0.30
HMV (ng/ml) Control 8 12.45 4.44 12.86 7.46 F= 0.86 P= 0.36
“Blackadder” 14.20 5.34 10.85 4.51
DOPAC (ng/ml) Control 8 3.55 1.51 4.64 4.82 F= 0.85 P= 0.36
“Blackadder” 3.90 1.61 3.22 0.94
Noradrenaline (ng/ml) Control 7 0.65 0.14 0.50 0.21 F= 6.70 P= 0.16
“Blackadder” 0.40 0.12 0.54 0.13
Normetadrenaline Control 8 0.46 0.14 0.37 0.17 F= 5.28 P= 0.03*
(ng/ml) “Blackadder” 0.27 0.17 0.52 0.32
Serotonin Control 7 27.24 17.55 17.49 23.60 F= 0.14 P= 0.71
(ng/ml) “Blackadder” 30.63 25.17 15.28 13.14
Dopamine Control 8 0.41 0.44 0.22 0.17 F= 2.97 P= 0.96
(ng/ml) “Blackadder” 0.14 0.10 0.51 0.77
DOPA Control 7 1.39 0.55 1.52 0.76 F= 1.16 P= 0.29
(ng/ml) “Blackadder” 1.73 0.69 1.31 0.83
PEA Control 7 0.05 0.03 0.05 0.03 F= 0.65 P= 0.42
(ng/ml) “Blackadder” 0.04 0.03 0.06 0.04
DHGP Control 7 1.37 0.31 1.22 0.66 F= 2.68 P= 0.11
(ng/L) “Blackadder” 0.95 0.15 1.28 0.34
Monoamine oxidase-B (MAO-B); Homovanillic acid (HVA); 3,4-Dihydroxyphenylacetic (DOPAC); Dihydroxyphenylalanine (DOPA);
phenylethylamine (PEA); 3,5-Dihydroxyphenylglycine (DHPG).
Figure 2 “Unchanged” raw values for platelet MAO-B activity (a) and blood plasma prolactin levels (b) and blood glucose levels
(c) and plasma 3,4-dihydroxyphenylglycol (DHPG) (d) t(P< 0.1). Shaded areas depict increments where P< 0.05 in the
treatment*increment pairwise comparisons. Open circles depict control and closed circles depict “Blackadder” juice.
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anthocyanins do not occur until one to two hours post
oral consumption24, making it unlikely that they
explain the effects seen at 15 min in the current
study. Coupled with the inability of a blackcurrant
anthocyanin-enriched extract (DelcyanTM) to inhibit
platelet MAO-B in our previous publication7, these
data suggest that anthocyanins are not likely to be
the compound driving MAO inhibition in vivo.
However, this does not rule out a synergy between
anthocyanins and lower molecular weight phenolic
components such as phenolic acids. Further research
needs to be conducted to attempt to identify the com-
ponents responsible for the observed MAO inhibition.
Plasma levels of 3,4-dihydroxyphenylglycol
(DHPG) levels were not significantly impacted after
the consumption of “Blackadder” juice. However,
the pattern observed highlights that DHPG was
reduced by ∼30% when compared to baseline at
100 min before rapidly returning to baseline by 3 h
post dose. As a proxy for MAO-A activity20 these
data indicate an inhibition of the MAO-A enzyme in
the periphery. AUC analysis showed no significant
differences in normetadrenaline up to 4 h after con-
sumption of “Blackadder” blackcurrant. However,
exploration of the data indicates approximately 100%
increase in normetadrenaline when compared to
control at 150 min, which indicates an increased
breakdown of adrenaline via catechol- methyl transfer-
ase (COMT) and is in line with our previous obser-
vation7 Analysis of data 24 h post consumption also
shows a significant increase in normetadrenaline, indi-
cating circulating normetadrenaline is still above base-
line 24h post dose. There were no other significant
changes in measured catecholamines or associated
metabolites between treatment groups.
As anticipated, peripheral prolactin was signifi-
cantly reduced after consumption of “Blackadder”
juice when compared to placebo, confirming our pre-
viously reported non-significant reductions.
Reductions were seen as early as 30 min post con-
sumption, with significantly lower area under the
curve increments beginning 45 min post dose and con-
tinuing until the last measured concentration at
240 min post dose. The maximal reduction appeared
at the 120 min epoch with a reduction of 61%. These
findings are consistent with inhibition of prolactin
secretion by the central D2 receptor agonist bromo-
criptine, 12 mg of which reduces peripheral prolactin
by∼ 60% two hours post dose25. Since dopamine
receptor agonists have been show to inhibit peripheral
prolactin secretion25,27, these data indicate the possi-
bility of a centrally active inhibition of MAO-B and
an increase in central dopamine levels after ingestion
of the “Blackadder” juice in healthy young men.
Although it must be noted that there are no reports
in the literature of direct interactions between
constituents found in blackcurrants and the suppres-
sion of prolactin excretion from the pituitary gland,
this mode of action cannot be ruled out.
With regards to blood glucose modulation, post
prandial profiles were not statistically different.
However, examination of the data showed that con-
sumption of “Blackadder” juice reduced the post-pran-
dial peak of blood glucose, and delayed the peak by
15 min when compared to the control beverage(see
Fig. 2C). Although not significant, a modulation of
blood glucose occurs until 100 min post consumption
of “Blackadder” juice when compared to the sugar
matched control with lower plasma levels until
∼35 min post dose. Higher blood glucose levels are
seen until 100 min post dose, after which glucose
levels return to a level similar to control and remain
that way until the last measured time point at 240 min
post dose. Blood glucose followed a similar pattern of
modulation described by Törrönen et al.,28 and
Wilson et al.,29, with reduced levels from the first
post-dose measurement at 15 min until one hour post
dose. In the current study, glucose findings are
coupled with a non-significant reduction in post-pran-
dial lactate 15 min post consumption of “Blackadder”
blackcurrant when compared to control. As lactate is
a by-product of glucose metabolism, this further sup-
ports the hypothesis that the pattern of glucose modu-
lation was a result of moderately slowed glucose
absorption rather than an increase in metabolism.
Although samples in the current study were taken at
regular time points via cannulation, it must be noted
that the infrequent samples make the assumption that
the modulation in blood glucose is linear between
each sample. It would be beneficial to use such
methods as interstitial continuous glucose monitoring
as used by Dye et al., (2010) to allow for a full “real
time” profile of the effects of “Blackadder” blackcur-
rant upon blood glucose to be monitored.
Monoamine oxidase inhibitors have been high-
lighted as a tool to attenuate age related decline of be-
havioural performance and decrease susceptibility to
senile depression, Parkinson’s disease and
Alzheimer’s disease”8. Data from this current trial
provide invaluable pharmacodynamic information
pertaining to the impact of “Blackadder” blackcurrant
juice upon platelet MAO-B activity and peripheral
prolactin. The findings suggest a reversible non-selec-
tive inhibition of the MAO enzymes by
“Blackadder” juice, although a somewhat greater affi-
nity to MAO-B is indicated. These changes in MAO
inhibition were evident without a measurable accumu-
lation of monoamines in the periphery. Future
research should utilise blackcurrant’s reversible
MAO-inhibiting properties and assess its impact
upon cognitive functioning in a population at risk of
age-related cognitive decline.
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